Literature DB >> 2559921

Detection of immediate early, early and late antigens of human cytomegalovirus by flow cytometry.

D Schols1, R Snoeck, J Neyts, E de Clercq.   

Abstract

The development of selective inhibitors of human cytomegalovirus (CMV) should lead to a better understanding of the mode of replication of CMV. A flow cytometric method was developed to monitor the expression of CMV antigens in CMV-infected human embryonic lung fibroblasts. The procedure is based on an indirect immunofluorescence assay using monoclonal antibodies directed against CMV-specific (immediate early, early, late) antigens and goat anti-murine IgG labeled with fluorescein isothiocyanate. Flow cytometric analysis clearly distinguished between the uninfected and infected cell population. There was a time-dependent appearance of CMV-specific antigens and a close correlation between the multiplicity of infection and the ratio of infected to uninfected cells. The method allows an accurate determination of the percentage of CMV-infected cells in the whole cell population and of the time of appearance of the viral antigens.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2559921     DOI: 10.1016/0166-0934(89)90107-9

Source DB:  PubMed          Journal:  J Virol Methods        ISSN: 0166-0934            Impact factor:   2.014


  10 in total

1.  Activity of different antiviral drug combinations against human cytomegalovirus replication in vitro.

Authors:  R Snoeck; G Andrei; D Schols; J Balzarini; E De Clercq
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1992-12       Impact factor: 3.267

2.  Human cytomegalovirus infects Caco-2 intestinal epithelial cells basolaterally regardless of the differentiation state.

Authors:  A Esclatine; M Lemullois; A L Servin; A M Quero; M Geniteau-Legendre
Journal:  J Virol       Date:  2000-01       Impact factor: 5.103

3.  Development of a method for direct quantification of cytomegalovirus antigenemia by flow cytometry.

Authors:  B M Imbert-Marcille; N Robillard; A S Poirier; M Coste-Burel; D Cantarovich; N Milpied; S Billaudel
Journal:  J Clin Microbiol       Date:  1997-10       Impact factor: 5.948

4.  Comparative activity of selected antiviral compounds against clinical isolates of human cytomegalovirus.

Authors:  G Andrei; R Snoeck; D Schols; P Goubau; J Desmyter; E De Clercq
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1991-12       Impact factor: 3.267

5.  Rapid ganciclovir susceptibility assay using flow cytometry for human cytomegalovirus clinical isolates.

Authors:  J J McSharry; N S Lurain; G L Drusano; A L Landay; M Notka; M R O'Gorman; A Weinberg; H M Shapiro; P S Reichelderfer; C S Crumpacker
Journal:  Antimicrob Agents Chemother       Date:  1998-09       Impact factor: 5.191

6.  Flow cytometric determination of ganciclovir susceptibilities of human cytomegalovirus clinical isolates.

Authors:  J M McSharry; N S Lurain; G L Drusano; A Landay; J Manischewitz; M Nokta; M O'Gorman; H M Shapiro; A Weinberg; P Reichelderfer; C Crumpacker
Journal:  J Clin Microbiol       Date:  1998-04       Impact factor: 5.948

Review 7.  Applications of flow cytometry to clinical microbiology.

Authors:  A Alvarez-Barrientos; J Arroyo; R Cantón; C Nombela; M Sánchez-Pérez
Journal:  Clin Microbiol Rev       Date:  2000-04       Impact factor: 26.132

8.  Double fluorescence analysis of human cytomegalovirus (HCMV) infected human fibroblast cultures by flow cytometry: increase of class I MHC expression on uninfected cells and decrease on infected cells.

Authors:  M Steinmassl; K Hamprecht
Journal:  Arch Virol       Date:  1994       Impact factor: 2.574

9.  The N-7-substituted acyclic nucleoside analog 2-amino-7-[(1,3-dihydroxy-2-propoxy)methyl]purine is a potent and selective inhibitor of herpesvirus replication.

Authors:  J Neyts; G Andrei; R Snoeck; G Jähne; I Winkler; M Helsberg; J Balzarini; E De Clercq
Journal:  Antimicrob Agents Chemother       Date:  1994-12       Impact factor: 5.191

10.  Activity of the anti-HIV agent 9-(2-phosphonyl-methoxyethyl)-2,6-diaminopurine against cytomegalovirus in vitro and in vivo.

Authors:  J Neyts; F Stals; C Bruggeman; E De Clercq
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1993-06       Impact factor: 3.267

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.